MEDINCELL.
LIVE

Serial Number

79413864

Owner

MedinCell S.A.

Attorney

Jonathan M. Gelchinsky

Filing Date

Oct 17, 2024

Add to watchlist:

No watchlists yet
View on USPTO

MEDINCELL. Trademark

Serial Number: 79413864 • Registration: 8299580

MEDINCELL. is a trademark filed by MedinCell S.A. on October 17, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

MedinCell S.A. (5 trademarks)

3 rue des Frères Lumière

Entity Type: 98

Trademark Details

Filing Date

October 17, 2024

Registration Date

June 16, 2026

Published for Opposition

April 28, 2026

Goods & Services

Laboratory research, testing and research laboratory analysis services in the field of drug delivery; laboratory services, namely, medical research laboratories; chemical analysis; medical, scientific and industrial research in the field of long-acting injectable compositions and providing information relating thereto; pharmaceutical drug development services; pharmaceutical research and development services; rental of laboratory apparatus and instruments; design and development of laboratory and diagnostic apparatus; development and testing of algorithms and software; consultancy in the field of pharmaceutical research and development; services for assessing the efficiency of pharmaceuticals; providing medical and scientific research information in the field of pharmaceuticals, chemical analysis and clinical trials; providing scientific research information; scientific research in the fields of medicine, pharmacology and veterinary medicine

Scientific apparatus and instruments, namely, tools for injecting and administering liquid formulations into testing equipment or other drug delivery devices; laboratory apparatus and instruments for extracting excipients or active pharmaceutical ingredients from in situ forming depots, not for medical purposes; apparatus and instruments for chemical analysis, namely, plates, glass slides or chips having multi-well arrays that can be used in chemical analysis; apparatus and instruments for measuring, testing and analysing chemical compositions; apparatus for analysing gases; weighing apparatus and instruments; measuring apparatus and instruments, namely, flow controllers; recorded or downloadable computer software for the quantitative long-term monitoring of the release pharmaceutical ingredients into a patient's body; computer hardware

Pharmaceutical preparations and substances for use in contraception, for the treatment of schizophrenia, bipolar disorder, bipolar depression, and major depressive disorders, and for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; veterinary preparations and substances for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, diseases and disorders, and for the treatment of substance abuse related diseases and disorders; pharmaceutical compositions for use in contraception, for the treatment of schizophrenia, bipolar disorder, bipolar depression, and major depressive disorders, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, diseases and disorders, and for the treatment of substance abuse related diseases and disorders; chemical preparations for medical or pharmaceutical use for use in contraception, for the treatment of schizophrenia, bipolar disorder, bipolar depression, and major depressive disorders, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; carriers for pharmaceutical and veterinary preparations being drug delivery agents in the form of dissolvable films, and coatings for tablets that facilitate the delivery of pharmaceutical and veterinary pharmaceutical preparations for use in contraception, for the treatment of schizophrenia, bipolar disorder, bipolar depression, and major depressive disorders, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; bacteriological culture or cell culture mediums for pharmaceutical and veterinary preparations being drug delivery agents comprised of compounds for facilitating the delivery of pharmaceutical and veterinary pharmaceutical preparations for use in contraception, for the treatment of schizophrenia, bipolar disorder, bipolar depression, and major depressive disorders, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; pharmaceutical and veterinary preparations and substances for subcutaneous delivery for use in contraception, for the treatment of schizophrenia, bipolar disorder, bipolar depression, and major depressive disorders, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders

Filing History

NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jun 18, 2026 OPNX
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 16, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 16, 2026 R.PR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 1, 2026 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
May 31, 2026 OPNR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 28, 2026 NPUB
PUBLISHED FOR OPPOSITION
Apr 28, 2026 PUBO
NOTIFICATION PROCESSED BY IB
Apr 23, 2026 GPNX
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 22, 2026 NONP
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Apr 8, 2026 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Apr 8, 2026 OP2R
APPROVED FOR PUB - PRINCIPAL REGISTER
Mar 28, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 27, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 27, 2026 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Mar 27, 2026 TROA
REFUSAL PROCESSED BY IB
Nov 15, 2025 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Oct 29, 2025 RFCS
REFUSAL PROCESSED BY MPU
Oct 29, 2025 RFRR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Oct 2, 2025 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Oct 2, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Oct 2, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Oct 2, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Oct 2, 2025 COAR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Sep 11, 2025 RFCR
NON-FINAL ACTION WRITTEN
Sep 10, 2025 CNRT
ASSIGNED TO EXAMINER
Sep 6, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Sep 5, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 5, 2025 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 2, 2025 REPR